In February 2023, the US Food and Drug Administration granted accelerated approval for Travere's Filspari (sparsentan) to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥1.5 g/g.

Travere expects Filspari to be available in the first quarter of 2023, and will be providing a comprehensive patient support program throughout the patient’s treatment journey.

In the second half of 2023, Travere and its collaborator CSL Vifor, anticipate a review decision by the European Medicines Agency regarding a possible conditional marketing authorization for the drug in Europe.